

Journal of Health Education



http://journal.unnes.ac.id/sju/index.php/jhealthedu

Determinants of Dengue Hemorrhagic Fever Deaths: A Hospital-Based Cross-Sectional Study

Rizki Mailiana[™], Lukman Fauzi Universitas Negeri Semarang Indonesia

Article Info

Article History: Submitted 03 January 2023 Accepted 31 March 2024 Published 29 Juli 2024

Keywords: Dengue Hemorrhagic Fever; Mortality; Risk Factors; Medical Records

DOI https://doi.org/10.15294/jhe. v9i1.10056

Abstract

Background: The increase in the dengue mortality rate in Indonesia and its risk factors which must be addressed immediately. Brebes Hospital, a hospital that is the primary referral for health centers and clinics in Brebes Regency, has a dengue mortality rate (Case Fatality Rate) of 7.88%, contributing to the first death rate in Brebes Regency. Data related to dengue deaths, such as comorbidities and hematocrit levels in dengue patients, were unavailable at the provincial and Brebes district levels, especially at Brebes Hospital. This study aims to determine the determinants of dengue death in inpatients at Brebes Hospital.

Methods: This cross-sectional study used medical record data of dengue inpatients from September 2021 to August 2022, with as many as 138 respondents using a simple random sampling technique. The research instrument is an observation sheet, including age, gender, incidence of thrombocytopenia, hypotension, hematocrit levels, hemoglobin levels, diabetes mellitus status, hypertension status, comorbidities, and LOS. The data were analyzed in univariate, bivariate with the chi-square test, and multivariate with a logistic regression test. **Results:** The bivariate analysis results showed that the variables of hypertension status, DM status, thrombocytopenia, hematocrit levels, and the presence of comorbid diseases were associated with dengue mortality (p<0.01). Multivariate analysis showed that after controlling for other variables, the risk of comorbid diseases was significant 27.54 times (p-value <0.001; AOR= 27.54; 95% CI= 7.21-105.07), and hematocrit levels were at risk of 4.96 times increasing dengue mortality (p-value = 0.005; AOR= 4.69; 95% CI= 1.59-13.83).

Conclusion: Hematocrit levels and the presence of comorbid diseases are critical determinants of dengue case mortality. The central comorbid diseases are hypertension, diabetes, and stroke. These two factors must be the primary concern of the clinicians in charge of patients in anticipation of an emergency.

p-ISSN 2527-4252 e-ISSN 2528-2905

[™] Correspondence Address: Email : rizkimailiana@students.unnes.ac.id

INTRODUCTION

The incidence of dengue has increased substantially, based on data from 76 countries, with the highest number of infections in Asian countries (Stanaway et al., 2016). Indonesia is one of the countries where dengue cases are still a health problem. The Incidence Rate (IR) of Dengue is still below the national target in 2021, 27 per 100,000 people. Moreover, the Case Fatality Rate (CFR) due to dengue increased in 2021 by 0.96% compared to 2020 by 0.69%. The province with the highest dengue death cases in Indonesia in 2021 is Central Java Province (Kemenkes RI, 2021). The dengue mortality rate in Central Java Province reached 2.71% in 2021, in the high category above 1%, exceeding the national target.

Brebes Regency has a CFR dengue mortality rate above the national target of 2.95% in 2020. There was a significant increase in CFR DHF in Brebes Regency between 2019 and 2020, from 1.43% to 2.95% (Brebes Regency Health Office, 2020). Brebes Regency ranks in the top 16 districts with the highest dengue cases in Central Java. However, the Brebes Regency does not rank highest in Central Java; this certainly does not make the Brebes Regency free from the threat of dengue deaths, with CFR numbers above the national target. Brebes Hospital is the primary referral for dengue patients from health centers and clinics in the Brebes Regency area (Brebes Hospital, 2022), with a mortality rate of 7.88% of dengue cases.

Dengue deaths are influenced by several factors, including age, comorbid diseases, and increased hematocrit levels (Mallhi et al., 2017). Patients with thrombocytopenia are significantly associated with dengue deaths (Pinto et al., 2016). Decreased platelet levels are associated with increased dengue mortality, which is identified as a risk factor for mild to moderate bleeding and causes bleeding complications (Hassan et al., 2020). An increase in hematocrit and a decrease in platelet count increase the likelihood of heavy bleeding (de Cavalcanti, 2014; Htun, 2021).

Based on the characteristics of dengue patients, Sangkaew (2021) noted that the female sex has a higher risk of becoming severe than men. This risk is related to differences in health-seeking behavior and the

immunological system. Another study revealed that low hemoglobin levels and length of stay (LOS) were significantly associated with dengue deaths associated with plasma leakage (Farida, 2022; Shahid Ansari, 2021). The presence of diabetes increases the risk of dengue severity by 2.12 times more (Agrawal et al., 2018) because there is a disorder of the immune system that proinflammation with endothelial discourse (N. S. N. Htun et al., 2015), while the existence of hypertension is significantly related to dengue deaths (Baqi, 2022; Foed-Portilla, 2021). The analysis report on the determinants of dengue cases in Indonesia has not been found, so it is essential to understand this. This study aims to determine the determinants of dengue deaths, analyzed from data of inpatients at Brebes Regency Hospital.

METHODS

This type of research was observational analytical with cross-sectional studies. The population of this study was 1334 respondents. The sample in this study was patients with a primary diagnosis of dengue fever recorded in the medical record data of Brebes Hospital in September 2021-August 2022. One hundred thirty-eight samples consisted of 43 deceased dengue patients and 95 recovered dengue patients obtained using simple random sampling techniques. The flow chart of patient selection and grouping is shown in Figure 1.

The data used is secondary data on the medical records of dengue inpatients from September 2021 to August 2022 at Brebes Hospital and is recorded in the reporting of dengue domestic hospitals from September 2021 to August 2022. The variables studied were dengue death, age, gender, incidence of thrombocytopenia, hypotension, hematocrit levels, hemoglobin levels, diabetes mellitus status, hypertension status, comorbidities, and LOS.

This research instrument was an observation sheet used to record data on the variables of the research part. Univariate and bivariate data processing applications, such as the chi-square test and Fisher test, carried out data analysis. This research has been approved by the Health Research Ethics Commission, Faculty of Sports Sciences, Semarang State University with Number 429//KEPK/EC/2022.




Figure 1. Patient Selection and Grouping Flow Diagram

RESULTS AND DISCUSSION

The results of data analysis from 138 patients showed that female patients were more than male patients, predominantly children of age, and had not worked. About a quarter of patients have comorbid diseases, with the identified types of diseases being hypertension and DM, with a proportion below 10%. The clinical condition of most patients with mild/typical thrombocytopenia, more than half with low Hb levels of \leq 12 dl, almost a quarter with an increase in hematocrit >42%, and most patients are treated <5 days.

Bivariate analysis shown in Table 2, eplain the results were obtained that the status of diabetes mellitus, hypertension status, thrombocytopenia, and the presence of comorbidities were significantly correlated

to the risk of dengue death in hospitalized patients. These results were inversely to gender, hemoglobin levels, hematocrit levels, hypotension, and LOS (length of stay), which showed insignificant results related to dengue death in hospitalized patients.

The relationship between gender and dengue mortality in this study showed no significant relationship with a value of p=0.26 (PR=1.40; 95% CI: 0.84-2.33). The results of this study were align with the research conducted by Abualamah (2020), indicating that there was no difference between gender and dengue deaths. However, it is different from the results of the research by Sangkaew (2021), that gender is a factor in the occurrence of dengue deaths. The female sex is associated with a higher risk for severe dengue due to differences in the immune systems of men and women.

Table 1. Distribution of Research Respondents

Variable	Frequency (n)	Percent (%)	
Gender			
Woman	72	52.2	
Legal Law	66	47.8	
Age			
1-14 years	78	56.5	
15 – 55 years old	31	22.5	
>55 years	29	21.0	
Work			
Unemployed	87	63.0	
Housewives	20	14.5	
Labor	1	0.7	
Merchant	2	1.4	
Farmer	4	2.9	
Driver	2	14.0	
Self-employed	10	7.2	
Retired	7	5.1	
Civil Servant	5	3.6	
Hypertension Status			
Yes	13	9.4	
No	125	90.6	
Diabetes Mellitus Status			
Yes	8	5.8	
No	130	94.2	
Thrombocytopenia			
Severe	5	3.6	
Light/Normal	133	96.4	
Hemoglobin			
≤12 g/dl	71	51.4	
>12 g/dl	67	48.6	
Hematocrit			
≥42%	32	23.2	
<42%	106	76.8	
Hypotension			
Yes	14	10.1	
No	124	89.9	
Existence of Comorbid Diseases			
Yes	36	26.1	
No	102	73.9	
LOS			
>5 days	29	21.0	
≤5 days	109	79.0	

Table 2. Results of Bivariate Analysis of Research

Variable	Status Responding					
	Die		Recover		p-value	PR (95% CI)
	N	%	N	%		
Gender						
Woman	26	36.1	46	63.9	0.25	1.40 (0.84-2.33)
Man	17	25.8	49	74.2		1.40 (0.64-2.55)
Hypertension Status						
Ys	11	84.6	2	15.4	<0.001*	2 20 (2 26 4 92)
No	32	25.6	93	74.4	<0.001	3.30 (2.26-4.82)
Diabetes Mellitus Status						
Yes	7	87.5	1	12.5	0.001*	3.16 (2.15-4.62)
No	36	27.7	94	72.3	0.001	
Thrombocytopenia						
Severe	4	80	1	3.4	0.02*	2.72 (1.62.4.55)
Light/Normal	39	29.3	94	70.7	0.03*	2.72 (1.63-4.55)
Up to Hemoglobin						
≤12 g/dl	25	35.2	46	64.8	0.38	1.31 (0.79-2.17)
>12 g/dL	18	26.9	49	73.1		
Up to Hematocrit						
≥42%	16	50.0	16	50.0	0.014	1.06 (1.22.2.15)
<42%	27	25.5	79	74.5	0.01*	1.96 (1.22-3.15)
Hypotension						
Yes	5	35.7	9	64.3	0.76	1 16 (0 55 2 47)
No	38	30.6	86	69.4	0.76	1.16 (0.55-2.47)
Existence of Comorbid Diseases						
Yes	29	80.6	7	19.4	0.0014	= 0.c (2 =1 0 =0)
No	14	13.7	88	86.3	<0.001*	5.86 (3.51-9.79)
LOS						
>5 days	11	37.9	18	62.1	0.51	1 20 (0 74 2 22)
≤5 days	32	29.4	77	70.6	0.51	1.29 (0.74-2.23)

^{*}Significant (p<0,05); LOS (*Length of stay*)

Table 3. Multivariate Analysis of Determinants of Dengue Death in Hospitalized Patients

Variable	В	Wald	p-value	AOR (95% CI)
The existence of comorbid diseases	3.316	23.553	<0.001	27.54 (7.21-105.07)
Hematocrit Level	1.546	7.857	0.005	4.69 (1.59-13.83)

Based on the results of the study, 84.6% of cases died in patients with hypertension status, and 74.4% of patients with recovered cases tended to patients who did not have hypertension status. The statistical test results in Table 1 showed an effect between hypertension status and dengue mortality with a p-value of <0.001 (PR=3.30; 95% CI: 2.26-4.82). This research is in line with the research done by Fonseca-Portilla (2021) 24,495 cases of dengue were identified, indicating that people with hypertension had a 2.45 times higher risk of

death than patients without hypertension.

Other studies by Baqi (2022), also stated that patients with hypertension are 5.76 times more likely to die than non-hypertensive patients. Hypertension often appears with underlying risk factors such as glucose disorders or diabetes mellitus, obesity, and high blood cholesterol levels (Fauzi et al., 2019). Hypertension causes damage to blood vessels and endothelial dysfunction, as well as inflammation of the endothelium and changes in vascular flow (Wang et al., 2019). Damage

of endotel in blood vessels as an indicator of plasma leakage refers to hypovolemic shock, which results in tissue anoxia, metabolic acidosis, and death (Nurminha et al., 2018).

Diabetes mellitus is one of the leading comorbidities of mortality and morbidity globally, especially in Asia. Table 2 shows a relationship between diabetes mellitus status and dengue mortality with a value of p=0.001 (PR=3.16; 95% CI: 2.15-4.62). Patients who experienced dengue death mostly had DM status (87.5%), while patients with recovered cases mostly did not have DM status (72.3%). Based on the analysis, the result of PR = 3.16 was given, meaning that patients with DM status had a 3.16 times risk of experiencing dengue death compared to patients without DM status. This research is aligned with the research conducted by Mallhi (2015), that people with DM status are at 2.8 times the risk of death from dengue. Diabetes mellitus can cause immune disorders and endothelial damage that affects the death of dengue (Pang et al., 2012).

Decreased platelet levels are closely related to the incidence of dengue, which can cause thrombocytopenia in dengue patients. Table 2 shows an association between thrombocytopenia and dengue mortality with p= 0.03 (PR=2.72; 95% CI: 1.63-4.5). Severe thrombocytopenia has a 2.72 times risk of dying from dengue fever. The results of this study are the research by Faridah (2022) It was revealed that patients with thrombocytopenia were associated with dengue death. Dengue in patients with low platelet levels will experience plasma leakage, which results in dengue death (Talukdar et al., 2021). In this study, 80% of patients who experienced death had severe thrombocytopenia, and in patients with recovered cases, mostly 70.7% had moderate and regular thrombocytopenia.

In the hemoglobin variable, a value of p=1.31 (PR = 1.31; 95% CI: 0.79-2.17) was obtained, meaning there was no relationship between hemoglobin levels and dengue death. The results of this study are not in line with the research by Faridah (2022) that hemoglobin levels have a significant effect on dengue mortality. However, the results of this study are in line with the research done by Hsieh (2017) stated that there was no association

between hemoglobin levels and dengue death. Based on this study, 25 patients died by having hemoglobin levels \leq 12 g/dL, and 18 patients died of dengue fever by having hemoglobin levels >12 g/dL.

Analysis of hematocrit levels and dengue mortality showed a significant relationship with a value of p=0.01 (PR=1.96; 95% CI: 1.22-3.15). This research is similar with the results conducted by Agrawal (2018), hematocrit levels ≥42%, causing a risk of death of 3.14 times that of dengue deaths. This research is not aligned with Married (2021), stated that there was no significant difference between hematocrit levels and dengue deaths, but an increase in hematocrit was related to the patient's platelet transfusion attempt. Based on this study, there were 16 patients with high hematocrit levels (≥42%) who died of dengue fever, while in recovered cases, there were 79 patients with low hematocrit levels (<42%).

Hypotension is systolic blood pressure <90mmHg (Rhodes et al., 2017). There were five patients (35.7%) who died of dengue fever by having hypotension, while 38 patients (30.6%) died without hypotension status. In Table 2, the analysis between hypotension and dengue mortality showed no relationship with a p-value 0.76 (PR 1.16; 95% CI: 0.55-2.47). The results of this study were not aligned with study done by General (2015) that the presence of hypotension in patients is associated with the risk of death from dengue. However, the results of this study are in line with study done by Agrawal (2018) showed that there was no difference between patients with hypotension status and patients without hypotension to dengue death.

Comorbidities such as hypertension, diabetes, chronic kidney disease, liver disease, and stroke are related to the risk of developing dengue that is getting worse (Guo et al., 2017; Kulkarni et al., 2019; Lee et al., 2020). In this study, 29 patients died with comorbidities, and 88 cases recovered without comorbidities. Table 2 shows a comorbid association with the death of dengue fever with p<0.001 (PR=5.86; 95% CI: 3.51-9.79). The results of this study were similar with the research by Werneck (2018) stated that comorbidities are associated with dengue deaths and research by Mallhi (2017)

that comorbidities are an essential condition that affects dengue patients. The existence of comorbidities that occur in the elderly contributes to the severity of dengue, apart from infection of dengue fever virus in dengue patients (Wei et al., 2016).

LOS is the time that indicates the length of care for the patient, from being recorded as an inpatient to being discharged from the hospital, either dead or recovered. In this study, patients who experienced death tended to have LOS >5 days (37.9%), and patients who recovered tended to have LOS ≤5 days (70.6%). Table 2 shows no association between LOS and dengue mortality with a value of p=0.51 (PR=1.29; 95% CI: 0.74-2.23). According to Ang (2019) A prolonged LOS is related to the incidence of dengue fever and affects the severity of the disease. Nevertheless, a study conducted in Trinidad showed that more severe diseases in patients can shorten LOS in hospitals. (Pooransingh et al., 2016).

The results of the analysis in Table 3 show that comorbidities (p-value <0.001; AOR= 27.54; 95% CI= 7.21-105.07) from hematocrit (p-value= 0.005; AOR= 4.69; 95% CI= 1.59-13.83) is the primary variable for dengue mortality in inpatients. Thus, it can be concluded that the most significant variable after controlling for other variables is the comorbid variable. The results of the analysis showed that dengue patients with comorbidities were 27.54 times at risk of dying from dengue compared to dengue patients who did not have comorbidities. The results of this study are in line with Toledo (2016) that comorbidities are associated with dengue deaths and research by Werneck (2018) people with comorbidities are 11 times at risk of dying from dengue fever. The existence of comorbidities such as cardiovascular disease, stroke, diabetes, hypertension, kidney disease, and respiratory diseases shows the potential for morbidity and mortality of dengue (Limkittikul, 2014; Pang, 2012; Toledo, 2016).

Hematocrit was a significant variable contributing 4.69 times increasing the risk of death of dengue patients. The results of this study are in line with the research conducted by Agrawal (2018), which found that increased hematocrit levels ≥42% in dengue patients cause

a risk of death of 3.14 times that of dengue. An increase in hematocrit levels is a predictor that causes plasma leakage and results in death. (Huy & Toan, 2022). In addition, increased hematocrit is one of the laboratory parameters related to dengue infection's severity and severe organ involvement. (Lam, 2017; Pang, 2012).

The mortality rate in dengue patients with a history of comorbidities requires appropriate treatment strategies and appropriate clinical care (WHO, 2012). The existence of comorbidities requires better protective measures against infection dengue fever in patients who have without specific comorbidities antiviral treatment. (Macias et al., 2021). An increase in hematocrit in patients can result in bleeding during dengue infection; therefore, monitoring the incidence of dengue fever is very important to determine the risk of hemoconcentration, which is an indicator of plasma leakage (Huy & Toan, 2022). Timely clinical management and early laboratory diagnosis in dengue patients with comorbidities are necessary for early detection of dengue case severity (WHO, 2012). In addition, medical treatment by doctors and nurses who have experience in developing dengue disease can reduce the mortality rate by less than 1% in most countries (WHO, 2018).

The strength of this study was the addition of new variables, such as the presence of comorbid diseases and the percentage of hematocrit levels in dengue patients, especially in Brebes Regency, where there has been no further research on the determinants of dengue mortality at Brebes Hospital so that further treatment can be carried out in dengue patients with comorbid diseases and high hematocrit levels. In addition, there were some limitations to this study. The use of medical record data that has not been computerized makes data lost, incomplete, and difficult to read. This study only used 138 respondents in one hospital, so it was insufficient to describe the determinants of dengue deaths in other regions. In addition, the study had not considered several factors related to dengue mortality due to unavailable data. The next researcher is expected to examine other variables through data collected by health professionals to analyze the clinical and epidemiological profile along with the determinants of dengue deaths.

CONCLUSION

The existence of comorbid diseases was at risk 27.54 times, while increased hematocrit levels contribute 4.69 times to the death of dengue cases. Clinicians and paramedics need to pay special attention and care to dengue patients with comorbid diseases and have elevated hematocrit levels to reduce the risk of death. Further research on the types of comorbid diseases and the critical value of hematocrit levels that affect the mortality of dengue cases.

REFERENCES

- Abualamah, W. A., Banni, H. S., Almasmoum, H. A., Allohibi, Y. A., Samarin, H. M., & Bafail, M. A. (2020). Determining Risk Factors for Dengue Fever Severity in Jeddah City, A Case Control Study (2017). *Polish Journal of Microbiology*, 69(3), 331–337. https://doi.org/10.33073/pjm-2020-036
- Agrawal, V. K., Saroj Kumar Prusty, B., Santosh Reddy, C., Reddy, G. K. M., Agrawal, R. K., & Bandaru, V. C. S. S. (2018). Clinical Profile and Predictors of Severe Dengue Disease: A Study From South India. *Caspian Journal of Internal Medicine*, 9(4), 334–340. https://doi.org/10.22088/cjim.9.4.334
- Baqi, A., Ur Rehman, F., Memon, P. S., & Omair, S. F. (2022). Prevalence and Outcomes of Myocarditis in Dengue-Infected Patients Admitted to a Tertiary Care Hospital of Low-Middle Income Country. Global Heart, 17(1), 1–9. https://doi.org/10.5334/GH.1129
- deChung, M. H., Chu, F. Y., Yang, T. M., Lin, H. J., Chen, J. H., Guo, H. R., Vong, S. C., Su, S. Bin, Huang, C. C., & Hsu, C. C. (2015). Hypotension, Bedridden, Leukocytosis, Thrombocytopenia And Elevated Serum Creatinine Predict Mortality in Geriatric Patients with Fever. *Geriatrics and Gerontology International*, 15(7), 834–839. https://doi.org/10.1111/ggi.12355
- de Cavalcanti, L. P. G., Martins Mota, L. A., Lustosa, G. P., Fortes, M. C., Martins Mota, D. A., Bezerra Lima, A. A., Coelho, I. C. B., & Mourão, M. P. G. (2014). Evaluation of the WHO Classification of Dengue Disease Severity during an Epidemic in 2011 in the State of Ceará, Brazil. *Memorias Do Instituto Oswaldo Cruz*, 109(1), 93–98. https://doi.org/10.1590/0074-0276140384
- Brebes Regency Health Office. (2020). *Health Profile* of Brebes Regency in 2020. Brebes Regency: Brebes Regency Health Office.

- Faridah, I. N., Dania, H., Chen, Y. H., Supadmi, W., Purwanto, B. D., Heriyanto, M. J., Aufa, M. A., Chang, W. C., & Perwitasari, D. A. (2022). Dynamic Changes of Platelet and Factors Related Dengue Haemorrhagic Fever: A Retrospective Study in Indonesian. *Diagnostics*, 12(4), 1–12. https://doi.org/10.3390/diagnostics12040950
- Fauzi, L., Rahayu, S. R., & Anggorowati, L. (2019).

 Determinants of Essential Hypertension among Young Adults in Suburban and Urban Areas in Semarang City, Indonesia.

 International Conference on Physical Education, Sport, and Health (ACPES 2019), 362, 297–300. https://doi.org/10.2991/acpes-19.2019.67
- Fonseca-Portilla, R., Martínez-Gil, M., & Morgenstern-Kaplan, D. (2021). Risk Factors for Hospitalization and Mortality due to Dengue Fever in a Mexican Population: A Retrospective Cohort Study. *International Journal of Infectious Diseases*, 110, 332–336. https://doi.org/10.1016/j.ijid.2021.07.062
- Guo, C., Zhou, Z., Wen, Z., Liu, Y., Zeng, C., Xiao, D., Ou, M., Han, Y., Huang, S., Liu, D., Ye, X., Zou, X., Wu, J., Wang, H., Zeng, E. Y., Jing, C., & Yang, G. (2017). Global Epidemiology of Dengue Outbreaks in 1990–2015: A Systematic Review and Meta-analysis. Frontiers in Cellular and Infection Microbiology, 7(JUL), 1–11. https://doi.org/10.3389/fcimb.2017.0031
- Hassan, J., Borhany, M., Abid, M., Zaidi, U., Fatima,
 N., & Shamsi, T. (2020). Coagulation
 Abnormalities in Dengue and Dengue
 Haemorrhagic Fever Patients. *Transfusion Medicine*, 30(1), 46–50. https://doi.org/10.1111/tme.12658
- Hsieh, C. C., Cia, C. T., Lee, J. C., Sung, J. M., Lee, N. Y., Chen, P. L., Kuo, T. H., Chao, J. Y., & Ko, W. C. (2017). A Cohort Study of Adult Patients with Severe Dengue in Taiwanese Intensive Care Units: The Elderly and APTT Prolongation Matter for Prognosis. *PLoS Neglected Tropical Diseases*, 11(1), 1–14. https://doi.org/10.1371/journal. pntd.0005270
- Htun, N. S. N., Odermatt, P., Eze, I. C., Boillat-Blanco, N., D'Acremont, V., & Probst-Hensch, N. (2015). Is Diabetes a Risk Factor for a Severe Clinical Presentation of Dengue?

 Review and Meta-analysis. *PLoS Neglected Tropical Diseases*, 9(4), 1–18. https://doi.org/10.1371/journal.pntd.0003741
- Htun, T. P., Xiong, Z., & Pang, J. (2021). Clinical Signs and Symptoms Associated with WHO Severe

- Sengue Classification: A Systematic Review and Meta-analysis. *Emerging Microbes and Infections*, 10(1), 1116–1128. https://doi.org/10.1080/22221751.2021.1935327
- Huy, B. V., & Toàn, N. V. (2022). Prognostic Indicators Associated with Progresses of Severe Dengue. *PLoS ONE*, 17, 1–11. https://doi.org/10.1371/journal.pone.0262096
- Ministry of Health of the Republic of Indonesia. (2021). *Indonesian Health Profile 2021*. Jakarta: Ministry of Health of the Republic of Indonesia.
- Kulkarni, A. V., Choudhury, A. K., Premkumar, M., Jain, P., Gupta, E., & Sarin, S. K. (2019). Spectrum, Manifestations and Outcomes of Dengue Infection in Individuals with and without Liver Disease. *Journal of Clinical* and Translational Hepatology, 7(2), 106–111. https://doi.org/10.14218/JCTH.2018.00047
- Lee, I. K., Hsieh, C. J., Lee, C. Te, & Liu, J. W. (2020). Diabetic Patients Suffering Dengue are at Risk for Development of Dengue Shock Syndrome/Severe Dengue: Emphasizing The Impacts of Co-existing Comorbidity(ies) and Glycemic Control on Dengue Severity. *Journal of Microbiology, Immunology and Infection*, 53(1), 69–78. https://doi.org/10.1016/j.jmii.2017.12.005
- Limkittikul, K., Brett, J., & L'Azou, M. (2014).

 Epidemiological Trends of Dengue Disease in Thailand (2000–2011): A Systematic Literature Review. *PLoS Neglected Tropical Diseases*, 8(11). https://doi.org/10.1371/journal.pntd.0003241
- Macias, A. E., Werneck, G. L., Castro, R., Mascareñas, C., Coudeville, L., Morley, D., Recamier, V., Guergova-Kuras, M., Etcheto, A., Puentes-Rosas, E., Baurin, N., & Toh, M. L. (2021). Mortality Among Hospitalized Dengue Patients with Comorbidities in Mexico, Brazil, and Colombia. American Journal of Tropical Medicine and Hygiene, 105(1), 102–109. https://doi.org/10.4269/ajtmh.20-1163
- Mallhi, T. H., Khan, A. H., Adnan, A. S., Sarriff, A., Khan, Y. H., & Jummaat, F. (2015). Clinico Laboratory Spectrum of Dengue Viral Infection and Risk Factors Associated with Dengue Hemorrhagic Fever: A Retrospective Study. *BMC Infectious Diseases*, 15(1), 1–12. https://doi.org/10.1186/s12879-015-1141-
- Mallhi, T. H., Khan, A. H., Sarriff, A., Adnan, A. S., & Khan, Y. H. (2017). Determinants of Mortality and Prolonged Hospital Stay among Dengue Patients Attending Tertiary Care Hospital: A Cross-sectional Retrospective Analysis. *BMJ Open*, 7(7), 1–12. https://doi.org/10.1136/

- bmjopen-2017-016805
- Nandwani, S., Bhakhri, B. K., Singh, N., Rai, R., & Singh, D. K. (2021). Early Hematological Parameters as Predictors for Outcomes in Children with Dengue in Northern India: A Retrospective Analysis. Revista Da Sociedade Brasileira de Medicina Tropical, 54, 1–7. https://doi.org/10.1590/0037-8682-0519-2020
- Nurminha, Sugiarti, M., & Aulia, M. G. (2018). The Relationship Between The Severity Of Dengue Fever And Albumin Levels In Dengue Hemorrhagic Fever Patients At Dr. H. Abdul Moeloek Relationship Degree Of Severity Dhf With Albumin To Patients Dengue Hemorrhagic Fever In RSUD Dr. H. Abdul Moeloek. *Journal of Health Analysts*, 7(1), 717–723.
- Pang, J., Salim, A., Lee, V. J., Hibberd, M. L., Chia, K. S., Leo, Y. S., & Lye, D. C. (2012). Diabetes with Hypertension as Risk Factors for Adult Dengue Hemorrhagic Fever in A Predominantly Dengue Serotype 2 Epidemic: A Case-Control Study. *PLoS Neglected Tropical Diseases*, 6(5). https://doi. org/10.1371/journal.pntd.0001641
- Pinto, R. C., De Castro, D. B., De Albuquerque, B. C., Sampaio, V. D. S., Passos, R. A. Dos, Da Costa, C. F., Sadahiro, M., & Braga, J. U. (2016). Mortality Predictors in Patients with Severe Dengue in the State of Amazonas, Brazil. *PLoS ONE*, 11(8), 1–10. https://doi.org/10.1371/journal.pone.0161884
- Pooransingh, S., Teelucksingh, S., & Dialsingh, I. (2016a). Dengue Deaths: Associated Factors and Length of Hospital Stay. *Advances in Preventive Medicine*, 2016, pp. 1–4. https://doi.org/10.1155/2016/6807674
- Pooransingh, S., Teelucksingh, S., & Dialsingh, I. (2016b). Dengue Deaths: Associated Factors and Length of Hospital Stay. *Advances in Preventive Medicine*, 2016, pp. 1–4. https://doi.org/10.1155/2016/6807674
- Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., Rochwerg, B., Rubenfeld, G. D., Angus, D. C., Annane, D., Beale, R. J., Bellinghan, G. J., Bernard, G. R., Chiche, J. D., Coopersmith, C., ... Dellinger, R. P. (2017). Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. In Intensive Care Medicine (Vol. 43, Issue 3). Springer Berlin Heidelberg. https://doi.org/10.1007/s00134-017-4683-6
- Sangkaew, S., Ming, D., Boonyasiri, A., Honeyford,

- K., Kalayanarooj, S., Yacoub, S., Dorigatti, I., & Holmes, A. (2021). Risk Predictors of Progression to Severe Disease During the Febrile Phase of Dengue: A Systematic Review and Meta-analysis. *The Lancet Infectious Diseases*, 21(7), 1014–1026. https://doi.org/10.1016/S1473-3099(20)30601-0
- Shahid Ansari, M., Jain, D., Harikumar, H., Rana, S., Gupta, S., Budhiraja, S., & Venkatesh, S. (2021). Identification of Predictors and Model for Predicting Prolonged Length of Stay in Dengue Patients. *Health Care Management Science*, 24(4), 786–798. https://doi.org/10.1007/s10729-021-09571-3
- Stanaway, J. D., Shepard, D. S., Undurraga, E. A., Halasa, Y. A., Coffeng, L. E., Brady, O. J., Hay, S. I., Bedi, N., Bensenor, I. M., Castañeda-Orjuela, C. A., Chuang, T. W., Gibney, K. B., Memish, Z. A., Rafay, A., Ukwaja, K. N., Yonemoto, N., & Murray, C. J. L. (2016). The Global Burden of Dengue: An Analysis from the Global Burden of Disease Study 2013. *The Lancet Infectious Diseases*, 16(6), 712–723. https://doi.org/10.1016/S1473-3099(16)00026-8
- Talukdar, S., Thanachartwet, V., Desakorn, V., Chamnanchanunt, S., Sahassananda, D., Vangveeravong, M., Kalayanarooj, S., & Wattanathum, A. (2021). Predictors of Plasma Leakage among Dengue Patients in Thailand: A Plasma-leak Score Analysis. *PLoS ONE*, 16(7 July 2021), 1–21. https://doi.org/10.1371/journal.pone.0255358
- Toledo, J., George, L., Martinez, E., Lazaro, A., Han, W. W., Coelho, G. E., Runge Ranzinger, S., & Horstick, O. (2016). Relevance of Non-communicable Comorbidities for

- the Development of the Severe Forms of Dengue: A Systematic Literature Review. *PLoS Neglected Tropical Diseases*, 10(1), 1–18. https://doi.org/10.1371/journal.pntd.0004284
- Wang, W. H., Lin, C. Y., Chang, K., Urbina, A. N., Assavalapsakul, W., Thitithanyanont, A., Lu, P. L., Chen, Y. H., & Wang, S. F. (2019). A Clinical and Epidemiological Survey of the Largest Dengue Outbreak in Southern Taiwan in 2015. *International Journal of Infectious Diseases*, pp. 88, 88–99. https://doi. org/10.1016/j.ijid.2019.09.007
- Wei, H. Y., Shu, P. Y., & Hung, M. N. (2016). Characteristics and Risk Factors for Fatality in Patients with Dengue Hemorrhagic Fever, Taiwan, 2014. American Journal of Tropical Medicine and Hygiene, 95(2), 322–327. https://doi.org/10.4269/ajtmh.15-0905
- Werneck, G. L., Macias, A. E., Mascarenas, C., Coudeville, L., Morley, D., Recamier, V., Guergova-Kuras, M., Puentes-Rosas, E., Baurin, N., & Toh, M. L. (2018). Comorbidities Increase in Hospital Mortality in Dengue Patients in Brazil. *Memorias Do Instituto Oswaldo Cruz*, 113(8), 1–5. https://doi.org/10.1590/0074-02760180082
- World Health Organization. (2012). Global Strategy for Dengue Prevention and Control 2012-2020. https://apps.who.int/iris/bitstream/handle/10665/75303/9789241504034_eng. pdf diakses pada 25 Agustus 2022.
- World Health Organization. (2018). *Dengue and Severe Dengue*. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue access on 18 Agustus 2022.